EAM
PLRX icon

Exome Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Exome Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-103,504
Closed -$1.36M – 76
2024
Q4 		$1.36M Sell
103,504
-46,096
-31% -$629K 1.02% 36
2024
Q3 		$1.68M Buy
149,600
+25,600
+21% +$320K 1.13% 39
2024
Q2 		$1.33M Buy
+124,000
New +$1.6M 1.19% 34
2024
Q1 		– Sell
-49,580
Closed -$898K – 67
2023
Q4 		$898K Buy
+49,580
New +$754K 0.89% 38

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Exome Asset Management's PLRX Position: Q1 2025 in Review

Exome Asset Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 103,504 shares — an estimated $1.36M sold.

Exome Asset Management first reported a position in PLRX in Q4 2023 and held it in 4 quarters. The position peaked at $1.68M in Q3 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Exome Asset Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Exome Asset Management sold 103,504 Pliant Therapeutics shares in Q1 2025, an estimated $1.36M.
  • Exome Asset Management first reported a position in Pliant Therapeutics in Q4 2023 and held it in 4 quarters.
  • Exome Asset Management's Pliant Therapeutics position peaked at $1.68M in Q3 2024.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.